Company

Arcutis Biotherapeutics, Inc.

Headquarters: Westlake Village, CA, United States

Employees: 147

CEO: Mr. Todd Franklin Watanabe M.A.

NASDAQ: ARQT +4.13%

Market Cap

$1.21 Billion

USD as of July 1, 2024

Market Cap History

Arcutis Biotherapeutics, Inc. market capitalization over time

Evolution of Arcutis Biotherapeutics, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Arcutis Biotherapeutics, Inc.

Detailed Description

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Arcutis Biotherapeutics, Inc. has the following listings and related stock indices.


Stock: NASDAQ: ARQT wb_incandescent

Details

Headquarters:

2945 Townsgate Road

Suite 110

Westlake Village, CA 91361

United States

Phone: 805 418 5006